Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor

• Main Authors: Pengxing He (Author), Shenghui Niu (Author), Shuai Wang (Author), Xiaojing Shi (Author), Siqi Feng (Author), Linna Du (Author), Xuyang Zhang (Author), Zhilu Ma (Author), Bin Yu (Author), Hongmin Liu (Author)
• Format: Book
• Published: Elsevier, 2019-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

EGFR tyrosine kinase inhibitor (EGFR-TKI) has been used successfully in clinic for the treatment of solid tumors. In the present study, we reported the discovery of WS-157 from our in-house diverse compound library, which was validated to be a potent and selective EGFR-TKI. WS-157 showed excellent i...